Trial Profile
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With Vildagliptin in Type 2 Diabetes Mellitus Patients ≥ 70 Years (Drug-naive or Inadequately Controlled on Oral Agents).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Feb 2015
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms INTERVAL
- Sponsors Novartis
- 27 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
- 23 May 2013 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met.
- 23 May 2013 Early online publication in the Lancet.